SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene ...

SOUTH SAN FRANCISCO, Calif., February 11, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be ...

Please provide your email address to receive an email when new articles are posted on . The genomic classifier test Decipher independently improved prognostication over clinicopathologic variables for ...

Imagine having increased muscle weakness for two years before figuring out the cause. That is the shared experience of myasthenia gravis patients. Canadian startup Decipher MedTech is developing a ...

SAN DIEGO, June 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement as a participating provider with Prime Health Services to provide ...

SAN DIEGO, Feb. 3, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement to provide its Decipher ® prostate cancer test to FEDMED Payors. FEDMED is ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier ...

Just three months ago, Veracyte laid out $600 million to buy Decipher Biosciences and its genomic prostate cancer test. Now, that diagnostic has racked up new data showing it can help identify ...

SOUTH SAN FRANCISCO, Calif., April 25, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic ...

The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients across the full ...

5-year patient-reported outcomes of bowel and urinary bother in the CHHiP trial (CRUK/06/016). Cost-effectiveness analysis of magnetic resonance imaging-ultrasound fusion biopsy versus systematic ...